Updates

ICYMI: Should the Specialty Drug Cost Debate Take a Breath? Data Proves Otherwise.

May 7, 2015

ICYMI: May 7, 2015 PharmaExec.com: “Take a Breath” on the Specialty Drug… Read More

ICYMI: Washington’s Role in High Drug Costs — Marketing Exclusivity and “Shadow Pricing”

May 6, 2015

ICYMI: May 6, 2015 National Journal: Washington’s Interest in Precision… Read More

ICYMI – Where’s Robert Stack When You Need Him?

May 5, 2015

ICYMI May 5, 2015 The New York Times: Runaway Drug Prices How companies set… Read More

ICYMI: High Drug Costs Impact Wall Street and Spark a New Initiative in the White House

Apr 28, 2015

April 28, 2015 Note: Distributing the New York Times article below is not an… Read More

ICYMI: Two WSJ Articles Highlight High Drug Prices

Apr 27, 2015

Two-fer ICYMI: Two WSJ Articles Highlight High Drug… Read More

National Coalition on Health Care highlights the impact of rising specialty drug prices

Apr 24, 2015

Originally published on AmericanPharmacyNews.com. Read More

Are Skyrocketing Drug Prices Really Needed for Innovation?

Apr 22, 2015

Are Skyrocketing Drug Prices Really Needed for Innovation? Amgen’s… Read More

ICYMI: National Journal article features CSRxP’s White Paper

Apr 21, 2015

This morning, the National Journal published an article regarding an increase in public concern over the high cost of prescription drugs. The article references CSRxP’s white paper, “Specialty Drug Hyperinflation: The Risk to Patients and the Health Care System.” Read More

Vertex’s Kalydeco combo could run payers $10M-plus per life, PBM figures

Apr 13, 2015

Sky-high drug prices have been causing their fair share of consternation among payers lately, and industry watchers have suspected for a while now that Vertex ($VRTX) will stir the pot when its new cystic fibrosis combo--expected to win FDA approval later this year--hits the market. But just how much will payers need to shell out for the new med over time? Prime Therapeutics has some ideas. Read More